Date: 2015-10-29
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: GlycoMimetics (USA - Md)
Product: rivipansel (GMI-1070)
Action mechanism: Rivipansel (GMI-1070) is a synthetic glycomimetic molecule, which was rationally designed to inhibit all three selectin types (a pan-selectin inhibitor). Selectins are glycoprotein cell adhesion molecules implicated in inflammatory processes. To achieve adequate therapeutic activity in certain inflammatory disorders, inhibition of all three selectin types (E-selectin, L-selectin and P-selectin) may be required. Rivipansel may have a number of additional potential applications, including hematologic cancers in which selectins may play a significant role. Selectin-mediated cell adhesion may result in chemotherapy resistance. Selectins have also been shown to facilitate dissemination of cancer cells to bone marrow. Initial evidence from preclinical blood cancer studies shows that rivipansel prevents selectin-mediated cancer cell adhesion and thereby renders cancer cells more sensitive to chemotherapy. Rivipansel has received both Orphan Drug and Fast Track status for VOC from the FDA. The subcutaneous formulation of rivipansel utilizes Enhanze™ Technology, licensed by Pfizer from Halozyme Therapeutics. This technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies components of the extracellular matrix in order to aid in the dispersion and absorption of other SC injected therapeutic drugs.
Disease:
Therapeutic area: Cancer - Oncology
Country: Belgium
Trial details:
Latest news: • On October 29, 2015, GlycoMimetics announced that the first healthy participant has been dosed with a subcutaneous formulation of rivipansel in a Phase 1, single ascending-dose clinical study to evaluate its safety, tolerability and pharmacokinetics. The Phase 1 study will recruit approximately 27 healthy participants and will be conducted at one center in Belgium.
